What is claimed is:

1. A pharmaceutical composition comprising a compound having the following formula (I):




wherein:

(a) X is CH or N;

(b) $R_1$ is hydrogen, alkyl, aralky, heteroaralkyl, alkenyl, aralkenyl, heteroaralkenyl, aryl, or heteroaryl;

(c) $R_2$ is hydrogen, alkyl, aralky, aryl, or heteroaryl;

(d) $R_{2'}$ is hydrogen unless $R_2$ is methyl, in which case $R_{2'}$ is also methyl;

(e) $R_3$ has the following formula (III):




wherein:

(i) $R_4$ is hydrogen, alkyl, halo, hydroxy, alkoxy, cyano, nitro, perfluoroalkyl, perfluoroalkoxy, or hydroxymethyl;

(ii) $R_5$ is hydrogen, alkyl, halo, alkoxy, cyano, nitro, perfluoroalkyl, perfluoroalkoxy, amino, aminocarbonyl, aminosulfonyl, or hydroxymethyl;

(iii) $R_6$ is alkyl, halo, alkoxy, perfluoroalkyl, perfluoroalkoxy, or nitro;

(iv) $R_4$ and $R_5$ when taken together can form a 5 or 6 membered ring and can contain one or more heteroatoms;

(v) $R_5$ and $R_6$ when taken together can form a 5 or 6 membered ring and can contain one or more heteroatoms;

(f) L is selected from the group consisting of $-(CH_2)_m-$, where m is an integer from 1 to 6, and an alkyl substituted hydrocarbyl moiety of the formula (IV):




wherein:

(i) n is 0, 1 or 2;

(ii) R7 and R8 are hydrogen, methyl or ethyl;

(iii) R9 and R9' are both hydrogen, methyl or ethyl;

(iv) if n is 1 and R7 or R8 is methyl or ethyl, then R9 and R9' are hydrogen;

(v) if n is 1 and R7 and R8 are hydrogen, then R9 and R9' are methyl or ethyl; and

(vi) if n is 2, then R9 and R9' are hydrogen and one or both of R7 and R8 are methyl or ethyl.

and pharmaceutically acceptable salts and esters thereof.

2. The pharmaceutical composition of claim 1, wherein $R_2$ and $R_{2'}$, are both hydrogen.

3. The pharmaceutical composition of claim 1, wherein $R_4$ is selected from the group consisting of hydrogen, halo, and alkoxy.

4. The pharmaceutical composition of claim 1, wherein $R_5$ is selected from the group consisting of hydrogen, alkyl, halo, alkoxy, and perfluoroalkyl;

5. The pharmaceutical composition of claim 1, wherein $R_6$ is selected from the group consisting of alkyl, halo, alkoxy, and perfluoroalkyl.

6. The pharmaceutical composition of claim 1, wherein $R_4$ and $R_5$ when taken together form a naphthalene ring; and

7. The pharmaceutical composition of claim 1, wherein $R_5$ and $R_6$ when taken together are selected from the group consisting of a methylenedioxy group and an ethylenedioxy group.

8. The pharmaceutical composition of claim 1, wherein L is an alkyl substituted hydrocarbyl moiety of formula (IV).

9. The pharmaceutical composition of claim 1, comprising a pharmaceutically acceptable excipient.

10. A method of treating a psychiatric or neurological condition, comprising the step of administering a therapeutic dose of the pharmaceutical composition of claim 1 to a patient in need thereof.

11. The method of claim 10, wherein the therapeutic dose is administered by an administrative route selected from the group consisting of intravenous infusion, oral, topical, intraperitoneal, intravesical, transdermal, nasal, rectal, vaginal, intramuscular, intradermal, subcutaneous and intrathecal routes.

12. The method of claim 10, wherein the therapeutic dose is in the range of 0.0001 mg/kg to 60 mg/kg.

13. The method of claim 10, wherein the condition being treated is a psychiatric condition.

14. The method of claim 10, wherein the condition being treated is pain.

15. The method of claim 10, wherein the condition being treated is emesis.

16. The method of claim 10, wherein the condition being treated is neurodegeneration.

17. Use of a pharmaceutical composition according to claim 1 for treating psychiatric and neurological conditions.

18. Use of a pharmaceutical composition according to claim 1 for the manufacture of a medicament for the treatment of psychiatric and neurological conditions.